130 related articles for article (PubMed ID: 28421968)
1. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
Byrd RA; Blackbourne JL; Knadler MP; Schultze AE; Vahle JL
Toxicol Pathol; 2017 Apr; 45(3):402-415. PubMed ID: 28421968
[TBL] [Abstract][Full Text] [Related]
2. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
[TBL] [Abstract][Full Text] [Related]
3. In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
Owens RA; Hansen RJ; Kahl SD; Zhang C; Ruan X; Koester A; Li S; Qian HR; Farmen MW; Michael MD; Moyers JS; Cutler GB; Vick A; Beals JM
J Pharmacol Exp Ther; 2016 Jun; 357(3):459-65. PubMed ID: 27026683
[TBL] [Abstract][Full Text] [Related]
4. Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.
Knadler MP; Nguyen TH; Campanale K; De Veer MJ; Beals JM; Li S; Hansen R; Siesky A; Michael MD; Porter CJ
Pharm Res; 2016 Dec; 33(12):2920-2929. PubMed ID: 27528391
[TBL] [Abstract][Full Text] [Related]
5. Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose.
Knadler MP; Ellis BB; Brown-Augsburger PL; Murphy AT; Martin JA; Wroblewski VJ
Drug Metab Dispos; 2015 Oct; 43(10):1477-83. PubMed ID: 26175543
[TBL] [Abstract][Full Text] [Related]
6. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
8. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
[TBL] [Abstract][Full Text] [Related]
9. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
[TBL] [Abstract][Full Text] [Related]
10. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Porksen N; Linnebjerg H; Garhyan P; Lam EC; Knadler MP; Jacober SJ; Hoevelmann U; Plum-Moerschel L; Watkins E; Gastaldelli A; Heise T
Diabetes Obes Metab; 2017 Apr; 19(4):482-488. PubMed ID: 27888561
[TBL] [Abstract][Full Text] [Related]
11. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
[TBL] [Abstract][Full Text] [Related]
12. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S; Henry RR; Ciaraldi TP; Armstrong DA; Burke PM; Pettus JH; Garhyan P; Choi SL; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen NK; Sinha VP; Linnebjerg H; Jacober SJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():17-24. PubMed ID: 27723226
[TBL] [Abstract][Full Text] [Related]
13. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
[TBL] [Abstract][Full Text] [Related]
14. Internalization and localization of basal insulin peglispro in cells.
Moyers JS; Volk CB; Cao JXC; Zhang C; Ding L; Kiselyov VV; Michael MD
Mol Cell Endocrinol; 2017 Oct; 454():23-38. PubMed ID: 28576743
[TBL] [Abstract][Full Text] [Related]
15. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
16. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.
Garg S; Selam JL; Bhargava A; Schloot N; Luo J; Zhang Q; Jacobson JG; Hoogwerf BJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():43-49. PubMed ID: 27393722
[TBL] [Abstract][Full Text] [Related]
17. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
[TBL] [Abstract][Full Text] [Related]
18. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
19. The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.
Pillai S; Duvvuru S; Bhatnagar P; Foster W; Farmen M; Shankar S; Harris C; Bastyr E; Hoogwerf B; Haupt A
Pharmacogenomics J; 2018 May; 18(3):487-493. PubMed ID: 29160303
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
Linnebjerg H; Choi SL; Lam EC; Mace KF; Hodgson TS; Sinha VP
Clin Pharmacol Drug Dev; 2016 May; 5(3):216-24. PubMed ID: 27163501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
